Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 USD | -9.04% | -13.27% | -18.91% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.91% | 289M | |
+14.84% | 121B | |
+18.31% | 112B | |
+4.45% | 22.57B | |
-18.26% | 20.82B | |
-17.26% | 16.19B | |
-42.36% | 16.17B | |
-14.23% | 16.3B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024